The sodium- and chloride-dependent glycine transporter 1 (SC6A9) was selected as a target for the schizophrenia treatment, the protein’s crystallographic structure has a low resolution (3.4 Å) and approximately 90 amino acid residues missing at the N-terminus of the chain. The gene discussed is SLC6A9; the disease is schizophrenia.